GlassScriptPhysician profile
Nirmal Pathak
NPI 1639602311
$4,490.62
in general payments reported to CMS, 2019-2025
15 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.28 · 2022: $74.01 · 2023: $667 · 2024: $1,874 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,331 · Food and Beverage: $670 · Education: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,331.25 |
| Food and Beverage | $669.62 |
| Education | $333.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,799.32 | 2024-2025 | Imfinzi, Epanova |
| Pfizer INC. | $1,745.48 | 2021-2025 | |
| Seagen INC. | $257.73 | 2023 | Adcetris, Tukysa |
| Amgen INC. | $124.36 | 2023 | Nplate |
| Apellis Pharmaceuticals, INC. | $101.50 | 2023 | Empaveli |
| Janssen Biotech, INC. | $99.99 | 2025 | Erleada |
| Takeda Pharmaceuticals U.S.A., INC. | $79.99 | 2023 | |
| Celgene Corporation | $70.54 | 2024 | Reblozyl |
| Array Biopharma INC | $54.14 | 2022-2023 | Xalkori, Lorbrena, Braftovi |
| Glaxosmithkline, LLC. | $40.51 | 2024 | Zejula, Jemperli |
| Astellas Pharma US INC | $29.98 | 2023-2024 | Xtandi |
| Regeneron Healthcare Solutions, INC. | $27.90 | 2023 | Libtayo |
| Sumitomo Pharma America, INC. | $27.54 | 2023 | Orgovyx |
| Merck Sharp & Dohme LLC | $18.75 | 2024 | Welireg, Keytruda, Lenvima |
| Mirati Therapeutics, INC. | $12.89 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirmal Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.